Canlyniadau Chwilio - Marc Ditmarsch

  • Dangos 1 - 8 canlyniadau o 8
Mireinio'r Canlyniadau
  1. 1
    Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

    Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? gan Nick S. Nurmohamed, Marc Ditmarsch, John J.P. Kastelein

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments

    Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments gan John J.P. Kastelein, Andrew Hsieh, Mary R. Dicklin, Marc Ditmarsch, Michael H. Davidson

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

    Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial gan Stephen J. Nicholls, Marc Ditmarsch, John J.P. Kastelein, Scott P. Rigby, Douglas Kling, Danielle Curcio, Nicholas John, Michael H. Davidson

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

    Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels gan Adam J. Nelson, Allan D. Sniderman, Marc Ditmarsch, Mary R. Dicklin, Stephen J. Nicholls, Michael H. Davidson, John J.P. Kastelein

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

    Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial gan Christie M. Ballantyne, Marc Ditmarsch, John J.P. Kastelein, Adam J. Nelson, Douglas Kling, Andrew Hsieh, Danielle Curcio, Kevin C. Maki, Michael H. Davidson, Stephen J. Nicholls

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

    Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial gan Mariko Harada‐Shiba, Michael H. Davdison, Marc Ditmarsch, Andrew Hsieh, Erin Wuerdeman, Douglas Kling, A. Nield, Mary R. Dicklin, Akitaka Nakata, Atsushi Sueyoshi, Satoshi Kuroyanagi, John J.P. Kastelein

    Cyhoeddwyd 2024
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

    The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial gan Kausik K. Ray, Marc Ditmarsch, David Kallend, Eric J. Niesor, Gabriela Suchánková, Ruchi Upmanyu, Judith Anzures‐Cabrera, Valerie Lehnert, Meike Pauly-Evers, Ingar Holme, Josef Šťásek, M. W. J. van Hessen, Peter J.H. Jones

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN

    Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADW... gan Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J.P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Návar, Steven E. Nissen, Anne C. Golberg, Liam R. Brunham, Danielle Curcio, Erin Wuerdeman, Annie Neild, Douglas Kling, Andrew Hsieh, Mary R. Dicklin, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael H. Davidson

    Cyhoeddwyd 2024
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: